Recursion Pharmaceuticals (RXRX) and Exscientia (EXAI) Shareholders Approve the Proposed Merger Nov 13, 2024 09:09AM
TD Cowen Reiterates Hold Rating on Exscientia PLC (EXAI) Oct 25, 2024 07:23AM
Exscientia (EXAI) Achieves Milestones for Two Programmes in Sanofi Collaboration Oct 16, 2024 07:03AM
Exscientia plc (EXAI) Reports Q2 Loss of $0.36/sh Aug 15, 2024 07:23AM
US SMID Caps: Here's the current state of play Aug 9, 2024 01:00PM


Aug 8, 2024 04:07PM TD Cowen Downgrades Exscientia PLC (EXAI) to Hold
Aug 8, 2024 07:41AM Recursion Pharmaceuticals (RXRX) to Merge with Exscientia (EXAI)
Jul 18, 2024 02:39PM TD Cowen Reiterates Buy Rating on Exscientia PLC (EXAI)
Jul 18, 2024 07:01AM Exscientia plc (EXAI) Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout
Jul 10, 2024 07:02AM Exscientia plc (EXAI) Launches AWS AI-powered Platform to Advance Drug Discovery
Jul 9, 2024 05:57AM TD Cowen Starts Exscientia PLC (EXAI) at Buy